Abstract
Introduction: Onychocytic matricoma (OCM) is a benign acanthoma of the nail matrix that presents with longitudinal melanonychia and nail thickening. Only 18 previously reported cases of OCM are in the literature since it was first described in 2012. Case Presentation: The purpose of this case report was to report a unique presentation of OCM in the toenail of a Black patient as well as to review the clinical presentation, histologic features, and management of this rare entity. Previously described cases presented on the fingernails and were predominantly in white males. Conclusion: OCM is a benign entity that may mimic a nail unit melanoma or squamous cell carcinoma especially when pachyonychia is present. Despite some clinical clues to suggest a diagnosis of OCM, a nail matrix biopsy is often required to rule out malignancy.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Perrin
C
, Cannata
GE
, Bossard
C
, Grill
JM
, Ambrossetti
D
, Michiels
JF
. Onychocytic matricoma presenting as pachymelanonychia longitudinal. A new entity (report of 5 cases)
. Am J Dermatopathol
. 2012
;34
(1
):54
–9
.2.
Wanat
KA
, Reid
E
, Rubin
AI
. Onychocytic matricoma: a new, important nail-unit tumor mistaken for a foreign body
. JAMA Dermatol
. 2014
;150
(3
):335
–7
.3.
Baran
R
, Moulonguet
I
, Goettmann Bonvallot
S
, Encaoua
R
, Robert
C
. Longitudinal subungual acanthoma: one denomination for various clinical presentations
. J Eur Acad Dermatol Venereol
. 2018
;32
(9
):1608
–13
.4.
Spaccarelli
N
, Wanat
KA
, Miller
CJ
, Rubin
AI
. Hypopigmented onychocytic matricoma as a clinical mimic of onychomatricoma: clinical, intraoperative and histopathologic correlations
. J Cutan Pathol
. 2013
;40
(6
):591
–4
.5.
Perrin
C
. Germinotropic onychocytic matricoma: a new histopathologic subtype of onychocytic matricoma in the light of the microanatomy of the normal nail unit, with special reference to nail mesenchyme
. Am J Dermatopathol
. 2017
;39
(7
):e97
–e101
.6.
Perrin
C
, Cannata
GE
, Langbein
L
, Ambrosetti
D
, Coutts
M
, Balaguer
T
. Acquired localized longitudinal pachyonychia and onychomatrical tumors: a comparative study to onychomatricomas (5 cases) and onychocytic matricomas (4 cases)
. Am J Dermatopathol
. 2016
;38
(9
):664
–71
.7.
Song
H
, Qu
F
, Dang
N
, Sun
X
. Onychocytic matricoma: report of an asian case
. Ann Dermatol
. 2017
;29
(3
):355
–7
.8.
Liao
YH
, Tsai
YJ
, Wu
WH
. Onychocytic matricoma: report of 2 cases and review of literature
. Dermatol Sin
. 2020
;38
(1
):43
.9.
Joo
HJ
, Kim
MR
, Cho
BK
, Yoo
G
, Park
HJ
. Onychomatricoma: a rare tumor of nail matrix
. Ann Dermatol
. 2016
;28
(2
):237
–41
.10.
Kusutani
N
, Kamo
R
, Sowa Osako
J
, Goto
K
, Ohsawa
M
, Yanagihara
S
. Onychocytic matricoma as an underrecognized benign mimicker of subungual malignant melanoma and Bowen’s disease
. J Dermatol
. 2017
;44
(4
):e73
–4
.11.
d’Almeida
LFV
, Jeunon
T
, Leverone
AP
, Nakamura
R
. Onychocytic matricoma
. An Bras Dermatol
. 2019
;94
(2
):214
–6
.12.
Perrin
C
, Langbein
L
, Ambrossetti
D
, Erfan
N
, Schweizer
J
, Michiels
J-F
. Onychocytic carcinoma: a new entity
. Am J Dermatopathol
. 2013
;35
(6
):679
–84
.13.
Zabolinejad
N
, Meibodi
NT
, Razmyar
M
, Torabi
S
. Subungual seborrhoeic keratosis
. Australas J Dermatol
. 2018
;59
(3
):e217
–8
.14.
Ongenae
K
, Van De Kerckhove
M
, Naeyaert
JM
. Bowen’s disease of the nail
. Dermatology
. 2002
;204
(4
):348
–50
.15.
Ruben
BS
. Pigmented lesions of the nail unit: clinical and histopathologic features
. Semin Cutan Med Surg
. 2010 Sep
29
3
148
58
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
